Dr. Park on Ongoing Research Efforts With CAR T-Cell Therapies in ALL

Video

Jae Park, MD, a hematologist oncologist at Memorial Sloan Kettering Cancer Center, discusses the use of CAR T-cell therapies in patients with acute lymphocytic leukemia.

Jae Park, MD, a hematologist oncologist at Memorial Sloan Kettering Cancer Center, discusses the use of CAR T-cell therapies in patients with acute lymphocytic leukemia (ALL).

Several different CAR T-cell products are examining ways to target CD19, says Park. For example, one product is a single-chain variable fragment that targets CD19. Preliminary data have been reported with the product in pediatric patients and it has been shown to result in a lower rate of cytokine release syndrome, says Park. If this study is further validated then that may present a safer option for adult patients with ALL.

Another CAR T-cell product is an allogeneic, off-the-shelf therapy, adds Park. Challenges exist with getting adult patients with aggressive disease autologous CAR T-cell products or generating T cells from these patients. To this end, off-the-shelf donor-derived CAR T-cell products are being investigated. Preliminary data with such products have been presented in the past, but an ongoing international study is evaluating the efficacy of this approach in a larger patient population, explains Park.

Additionally, ongoing studies are examining bispecific CAR T cells that are targeting CD19 and CD22 at the same time. The rationale for this approach is to reduce the rate of CD19-negative relapse by targeting 2 antigens simultaneously. The final data from this research are greatly anticipated, says Park. Other ongoing clinical studies are examining the efficacy of CAR T-cell therapies with the ultimate goal of providing safer and more effective products to adult patients with ALL; this continues to be a critical unmet need, concludes Park.

Recent Videos
Ben Samelson-Jones, MD, PhD, assistant professor pediatric hematology, Perelman School of Medicine, University of Pennsylvania and Associate Director, Clinical In Vivo Gene Therapy, Children’s Hospital of Philadelphia
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Steven W. Pipe, MD, a professor of pediatric hematology/oncology at CS Mott Children’s Hospital
Haydar Frangoul, MD, the medical director of pediatric hematology/oncology at Sarah Cannon Research Institute and Pediatric Transplant and Cellular Therapy Program at TriStar Centennial
David Barrett, JD, the chief executive officer of ASGCT
Georg Schett, MD, vice president research and chair of internal medicine at the University of Erlangen – Nuremberg
David Barrett, JD, the chief executive officer of ASGCT
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Caroline Diorio, MD, FRCPC, FAAP, an attending physician at the Cancer Center at Children's Hospital of Philadelphia
© 2024 MJH Life Sciences

All rights reserved.